Biocon Biologics settles with Amgen Inc to commercialise biosimilars in Europe
Published on: Dec. 2, 2025, 3:46 p.m. | Source: Daily Excelsior
NEW DELHI, Dec 2: Biocon Biologics on Tuesday said it has inked a settlement agreement with Amgen Inc., paving the path for the commercialisation of Denosumab biosimilars in Europe and the rest of the world. The agreement allows Biocon Biologics to commercialise both biosimilars — Vevzuo and Evfraxy — in Europe starting December 2, 2025. The other terms of the settlement remain confidential. “This settlement sets the stage for Biocon Biologics to bring our Denosumab biosimilars, Vevzuo and Evfraxy, to […]
